Intranasal Oxytocin for Stimulant Use Disorder Among Male Veterans Enrolled in an Opioid Treatment Program: A Randomized Controlled Trial
Autor: | Christopher S. Stauffer, Salem Samson, Alex Hickok, William F. Hoffman, Steven L. Batki |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Clinical Trials and Supportive Activities
Clinical Sciences RC435-571 methadone Substance Misuse Clinical Research oxytocin Behavioral and Social Science opioid-related disorders Psychology veterans Original Research Psychiatry Prevention Neurosciences Evaluation of treatments and therapeutic interventions stimulant Brain Disorders Psychiatry and Mental health Good Health and Well Being opiate substitution treatment 6.1 Pharmaceuticals Public Health and Health Services treatment adherence and compliance Mental health amphetamine-related disorders Drug Abuse (NIDA only) |
Zdroj: | Frontiers in Psychiatry, Vol 12 (2022) Frontiers in Psychiatry |
ISSN: | 1664-0640 |
DOI: | 10.3389/fpsyt.2021.804997 |
Popis: | The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current treatment options are limited. Oxytocin administration has shown promise in reducing addiction-related behavior and enhancing salience to social cues. We conducted a randomized, double-blind, placebo-controlled clinical trial of intranasal oxytocin administered twice daily for 6 weeks to male Veterans with stimulant use disorder who were also receiving opioid agonist therapy and counseling (n = 42). There was no significant effect of oxytocin on stimulant use, stimulant craving, or therapeutic alliance over 6 weeks. However, participants receiving oxytocin (vs. placebo) attended significantly more daily opioid agonist therapy dispensing visits. This replicated previous work suggesting that oxytocin may enhance treatment engagement among individuals with stimulant and opioid use disorders, which would address a significant barrier to effective care. |
Databáze: | OpenAIRE |
Externí odkaz: |